<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE GlossaryTerm >
<GlossaryTerm id="CDR0000601196"><TermName>brivanib</TermName><TermPronunciation>(brih-VAN-ib)</TermPronunciation><TermDefinition><DefinitionText>A substance being studied in the treatment of cancer. Brivanib may prevent the growth of new blood vessels that tumors need to grow and may kill cancer cells. It is a type of vascular endothelial growth factor receptor 2 inhibitor and a type of antiangiogenesis agent.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000720693" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;brivanib&quot;" language="en" id="_3"/><MediaLink ref="CDR0000720692" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;brivanib&quot;" language="es" id="_4"/><SpanishTermName>brivanib</SpanishTermName><SpanishTermDefinition><DefinitionText>Sustancia en estudio para el tratamiento de cáncer. El brivanib podría prevenir la formación de vasos sanguíneos nuevos que los tumores necesitan para crecer y podría destruir células cancerosas. Es un tipo de inhibidor del factor de crecimiento endotelial vascular 2 y un tipo de antiangiogénico.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2008-07-17</DateFirstPublished><DateLastModified>2009-04-21</DateLastModified></GlossaryTerm>
